Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Aachen – page 76

1 286 clinical trials in Aachen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aachen at a glance
1 286
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 286 trials in Aachen

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Diffuse large B-cell lymphoma

Not recruiting

Study of Copanlisib with Rituximab and CHOP for Untreated Diffuse Large B-Cell Lymphoma in Patients Aged 18-80

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:GermanyGermany
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Graft versus host disease+1

Not recruiting

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:DKMS Group gGmbH

Neoplasm

Not recruiting

Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:OMX-0407
  • Sponsor:iOmx Therapeutics AG

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Cough

Not recruiting

Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Chronic myeloid leukaemia

Not recruiting

Study of dose reduction strategy for tyrosine kinase inhibitors (imatinib, ponatinib, bosutinib, nilotinib, dasatinib) in patients with chronic myeloid leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Radboud universitair medisch centrum Stichting

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Aachen

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on lymphoma treatments and various forms of breast cancer therapies, including studies of novel immunotherapy combinations for head and neck cancers.

  • Diffuse Large B-Cell Lymphoma
  • Triple-Negative Breast Cancer
  • Non-small Cell Lung Cancer

Advanced therapeutic approaches including targeted treatments and combination therapies are being evaluated for improved patient outcomes.

02 Cardiovascular Studies

Research targeting heart failure prevention and management of cardiovascular complications, with emphasis on innovative drug combinations and preventive treatments.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Obesity-related Cardiac Conditions

Studies focus on reducing cardiovascular events and improving long-term patient outcomes.

03 Chronic Conditions

Clinical investigations addressing various chronic conditions, including inflammatory diseases and dermatological disorders.

  • Hidradenitis Suppurativa
  • Chronic Venous Ulcers
  • Inflammatory Myopathies

Evaluating new therapeutic approaches for managing long-term conditions and improving quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.